Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint
Crossref DOI link: https://doi.org/10.1007/s00228-014-1760-4
Published Online: 2014-10-12
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Diepstraten, Jeroen
Janssen, Esther J. H.
Hackeng, Christian M.
van Dongen, Eric P. A.
Wiezer, René J.
van Ramshorst, Bert
Knibbe, Catherijne A. J.
Text and Data Mining valid from 2014-10-12